<DOC>
	<DOCNO>NCT01700569</DOCNO>
	<brief_summary>O6-méthylguanine méthyltransférase ( MGMT ) main repair gene DNA lesion induce Temozolomide combination radiation therapy Glioblastoma ( GBM ) Stupp.R et al publish regimen . In preclinical model , demonstrate MGMT methylation ( silence DNA repair process ) achievable folic acid . About half patient operate GBM un-methylated MGMT gene status therefore poor prognosis . A phase-1 dose escalation study propose pharmacologic dos folinic acid combination temozolomide radiotherapy operate GBM .</brief_summary>
	<brief_title>Phase-1 Study Folinic Acid Modulate MGMT Gene Glioblastoma</brief_title>
	<detailed_description>Glioblastoma treat Stupp regimen ( Temozolomide + radiation therapy ) different outcome depend methylation status MGMT gene : gene unmethylated , repair process active prognostic poor . In pre-clinical model , demonstrate Folic acid could re-methylate MGMT gene therefore repair process radiation temozolomide could limit , allow good prognosis . The propose phase-1 study explore safety efficacy escalate dos oral Folinic acid concomitantly Stupp regimen . To determine MTD main objective study , toxicty profile , RDP2 methylation process efficacy MGMT gene level .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Operated GBM ( complete near complete resection ) Unmethylated MGMT gene Non operable GBM Methylated MGMT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>high-grade</keyword>
	<keyword>glioma</keyword>
	<keyword>epigenetic</keyword>
</DOC>